{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-065935","form_type":"8-K","ticker":null,"cik":"0001169245","company_name":"PhaseBio Pharmaceuticals Inc","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.545802+00:00","generated_at":"2026-06-04T22:49:28.035246+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PhaseBio settles SFJ dispute in Ch.11; $2.5M admin claim, $27.8M unsecured claims","bullets":["Settlement stipulates a $2.5M allowed administrative claim for SFJ, down from the $15.4M sought.","SFJ receives $27.8M in aggregate general unsecured claims under the settlement.","Plan requires sale of Bentracimab royalties within six months of BLA approval; if sale <$2.5M, royalty transfers to SFJ.","SFJ will withdraw its objection and support the amended Chapter 11 Plan after Bankruptcy Court approval.","November 2023 monthly report shows cash $2.55M, cumulative professional fees $14.2M, zero employees."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-065935","json":"https://secwatch.observer/filing/0001193125-24-065935.json","markdown":"https://secwatch.observer/filing/0001193125-24-065935.md","text":"https://secwatch.observer/filing/0001193125-24-065935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1169245/000119312524065935/0001193125-24-065935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1169245/000119312524065935/d759787d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:49:28.035246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65e6f628cabd59cb8c4fd546893ea69de5071cda","claim":"PhaseBio Pharmaceuticals Inc entered into Plan Support and Settlement Agreement with SFJ Pharma X, Inc. (effective 2024-03-06).","evidence_excerpt":"On March 6, 2024, the Company and SFJ executed and entered into a Plan Support and Settlement Agreement (the “Settlement Agreement”) to resolve the Motion to Allow, the Objection, and related matters.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1169245/000119312524065935/0001193125-24-065935-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"settlement"},{"label":"Counterparty","value":"SFJ Pharma X, Inc."},{"label":"Effective","value":"2024-03-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}